There is an urgent need for the discovery of new drugs against infectious diseases and cancer. Globally, infectious diseases are prevalent, with pathogens constantly evolving, leading to a rise in ...
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
Zacks Investment Research on MSN2d
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung CancerJ&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback